STAR · Strides Pharma Science Ltd · Biotechnology & Drugs
STAR · Strides Pharma Science Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
20.1% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 16 Oct 2026
Revenue (latest Q)
₹1,265 Cr
Revenue YoY
PAT YoY
+57.5%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
5.7
P/S (TTM)
2
Sector P/E
33.6
Dividend yield
+0.5%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| STAR (this stock) | 16.4 | 5.7 | +12.3% | +19.7% | 0.57 | +0.5% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
falling 2q
MF
8.73% (+0.17pp)
rising 1q
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
| canonicalSymbol | date | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| STAR | 2026-10-30 | 662369 | 1 | STRONG | BULK |
| STAR | 2026-08-28 | 1000000 | 1 | WEAK | BULK |
News timeline
- lowbusiness-standard.com· 20 Aug 2026, 10:08 amStrides Pharma surges 11% on USFDA EIR for flagship facility in Bengaluru
- lowthehindubusinessline.com· 20 Aug 2026, 07:00 am18 stocks including BSE, LIC, HDFC Bank, Aditya Infotech, Ramco Systems, Titagarh Rail, Gravita, Strides, Dr Lal Path in focus today
Concalls & investor presentations
AI-generatedKey takeaway: Strides Pharma Science Limited conducted its Q1 FY27 earnings conference call on July 31, 2026, where management provided an overview of the company's performance amidst ongoing geopolitical challenges. Management reported a 13% year-on-year growth in revenue, with Ex-US markets showing a 17% increase. Despite external pressures, EBITDA margins were maintained at 18.2%. The US business generated ₹6,282 million in revenue, with a focus on profitability and portfolio quality. Management highlighted the importance of controlled substances and niche domains for future growth. The Ex-US segment continued to expand, particularly in Europe and Africa. Management also noted improvements in their EcoVadis sustainability score and reaffirmed their long-term revenue aspirations. Financial highlights included a reported PAT of ₹165.5 crore, boosted by a gain from divesting a stake in Pivot Path. The call concluded with management expressing confidence in their strategic foundations and growth drivers.
Management emphasized steady growth and resilience despite external challenges.
Sourced from an exchange-filed transcript, dated 03 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Strides Pharma Science Limited conducted its Q4 and FY26 earnings conference call on May 18, 2026, where management highlighted a three-year journey focused on geographical diversification, profitability, and balance sheet strength. Management reported a revenue growth of 6.4% year-on-year for FY26, with a significant contribution from Ex-U.S. markets, which grew at a CAGR of 19%. EBITDA margins expanded to 19%, and operational PAT grew 18 times over three years. The U.S. business faced challenges due to a weaker flu season, impacting revenue, but management emphasized a strategic focus on profitability and disciplined capital allocation. The company announced a dividend of INR5 per share and highlighted a leadership update with the appointment of Ramaraju as Executive Director. Management expressed confidence in future growth driven by a strong pipeline and strategic partnerships, despite external cost pressures.
Management emphasized strong growth metrics and strategic advancements.
Sourced from an exchange-filed transcript, dated 21 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Strides Pharma Science Limited conducted its Q3 FY'26 earnings conference call on January 30, 2026, where management discussed key financial highlights and strategic priorities. Management reported a gross margin of 59.8% for the quarter, with a significant focus on profitability, geographical diversification, and balance sheet strength. The Ex-U.S. markets contributed 47% of revenues, showing a 20% year-on-year growth. The U.S. revenue remained flat at $70 million, attributed to a delayed flu season and the discontinuation of unprofitable products. Management highlighted a strong EBITDA growth of 12% year-on-year, with operational PAT increasing by 39%. The company also announced the appointment of Peter Hardwick as CEO of North American Business and Nandini Matiyani as Executive VP of HR. Additionally, Strides improved its ESG score from 75 to 80, reflecting its commitment to responsible growth and governance practices.
Management emphasized strong financial performance and strategic advancements.
Sourced from an exchange-filed transcript, dated 03 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedStrides Pharma Science Limited (STAR) reported FY2025-26 financial results with key highlights including a demerger of Arco Lab's Life Sciences and Digital Innovation businesses into Pivot Path, and acquisition of the remaining 50% stake in Neviton Softech for EUR 2 million. The company has no defaults in loan repayments or regulatory actions, and its internal financial controls were found effective with no material weaknesses. The audit noted key issues in impairment testing of non-current assets and gross-to-net sales adjustments, with significant judgment involved. The company faces ongoing tax disputes but has no material uncertainties affecting its going concern status.
- Completed demerger of Arco Lab's Life Sciences and Digital Innovation businesses into Pivot Path, pending NCLT approval.
- Acquired remaining 50% stake in Neviton Softech for EUR 2 million, enhancing IT and engineering capabilities.
- No defaults in loan repayments or regulatory actions noted.
- Internal financial controls were effective with no material weaknesses identified.
- Ongoing tax disputes for AY2020-24 under various forums, but no material uncertainty on going concern status.
Key takeaway: Strides Pharma Science Limited completed strategic business restructurings, maintained financial stability with no defaults, and faces manageable tax disputes without impacting its going concern status.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
1 occurrenceRecent (last 12 months)
The company informed the Stock Exchanges about changes in Senior Management Personnel on May 10, 2025, which was beyond the prescribed timeline, leading to a clarification request from BSE Limited on July 18, 2025.
Routine disclosures
Contingent Liability
3 occurrencesRecent (last 12 months)
The Group faces litigation from tax authorities over various tax positions, including deductibility of transactions, tax incentives, exemptions, and cross-border transfer pricing arrangements. The Group recognizes accruals for uncertain tax liabilities based on its best estimate.
Earlier (1-3 years ago)
The Group faces uncertainties in tax positions due to complexities in tax laws, interpretations, and litigation with authorities. These uncertainties may result in contingent liabilities as the Group assesses possible outcomes and considers accruals or contingent liabilities.
The company has uncertain tax positions that may result in contingent liabilities, with the Group recognizing accruals based on its best estimate of the outcome.
Related-Party Transaction
3 occurrencesRecent (last 12 months)
The company has listed several related parties, including associates and entities controlled by key management personnel and their relatives, with whom transactions occurred during the current or previous year.
Earlier (1-3 years ago)
The company has provided guarantees on behalf of OneSource Specialty Pharma Limited (formerly Stelis Biopharma Limited), India.
The company holds 11,089,320 shares in Onesource Specialty Pharma Limited, which is an associate. Note 43 refers to related party transactions.
Statutory dues in dispute
3 occurrencesRecent (last 12 months)
Strides Pharma Science Limited has undisputed statutory dues relating to Income Tax Act, 1961 for AY2020-21, with the dispute pending before CIT (Appeals)/Joint.
Earlier (1-3 years ago)
The company has statutory dues under the Income Tax Act and Central Excise Act pending before various tribunals and appeals commissions, with amounts totaling Rs. 668.56 million (approx.) as of 31 March 2025.
The company had delayed Provident Fund payments due to delays in obtaining Universal Account Numbers/Aadhar numbers for certain employees, and had disputes over income tax and central excise dues pending before regulatory forums.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
19.58% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18). Change vs the previous disclosure: increasing.